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ABSTRACT
Background Despite striking successes, 
immunotherapies aimed at increasing cancer- specific 
T cell responses are unsuccessful in most patients with 
cancer. Inactivating regulatory T cells (Treg) by inhibiting 
the PI3Kδ signaling enzyme has shown promise in 
preclinical models of tumor immunity and is currently 
being tested in early phase clinical trials in solid tumors.
Methods Mice bearing 4T1 mammary tumors were orally 
administered a PI3Kδ inhibitor (PI-3065) daily and tumor 
growth, survival and T cell infiltrate were analyzed in the 
tumor microenvironment. A second treatment schedule 
comprised PI3Kδ inhibitor with anti- LAG3 antibodies 
administered sequentially 10 days later.
Results As observed in human immunotherapy trials with 
other agents, immunomodulation by PI3Kδ-blockade led 
to 4T1 tumor regressor and non- regressor mice. Tumor 
infiltrating T cells in regressors were metabolically fitter 
than those in non- regressors, with significant enrichments 
of antigen- specific CD8+ T cells, T cell factor 1 (TCF1)+ 
T cells and CD69− T cells, compatible with induction of a 
sustained tumor- specific T cell response. Treg numbers 
were significantly reduced in both regressor and non- 
regressor tumors compared with untreated tumors. The 
remaining Treg in non- regressor tumors were however 
significantly enriched with cells expressing the coinhibitory 
receptor LAG3, compared with Treg in regressor and 
untreated tumors. This striking difference prompted us 
to sequentially block PI3Kδ and LAG3. This combination 
enabled successful therapy of all mice, demonstrating the 
functional importance of LAG3 in non- regression of tumors 
on PI3Kδ inhibition therapy. Follow- up studies, performed 
using additional cancer cell lines, namely MC38 and CT26, 
indicated that a partial initial response to PI3Kδ inhibition 
is an essential prerequisite to a sequential therapeutic 
benefit of anti- LAG3 antibodies.
Conclusions These data indicate that LAG3 is a key 
bottleneck to successful PI3Kδ-targeted immunotherapy 
and provide a rationale for combining PI3Kδ/LAG3 
blockade in future clinical studies.
INTRODUCTION
The efficacy of a tumor- specific immune 
response is influenced by the balance 
between tumor- infiltrating regulatory T cells 
(Treg) and tumor infiltrating CD4+ and CD8+ 
T cells (reviewed in Takeuchi and Nishi-
kawa1). Strategies in mice and humans have 
sought to deplete Treg, with some success,2–5 
supporting the drive to develop more 
effective, clinically relevant Treg- targeting 
approaches. Mouse and human studies have 
demonstrated that genetic or pharmaco-
logical inactivation of the phosphoinositide 
3- kinase δ (PI3Kδ) isoform of PI3K has the 
capacity to reduce the number of Treg and 
dampen their function.6–8
The PI3K family members that are directly 
involved in cell signaling comprise PI3Kα, 
PI3Kβ, PI3Kδ and PI3Kγ, of which PI3Kδ is 
expressed primarily by leukocytes.9 Small 
molecule inhibitors targeting single and 
multiple isoforms of PI3K have been devel-
oped, including the first approved PI3K 
inhibitor idelalisib (formerly GS-1101, 
CAL-101), a PI3Kδ-selective inhibitor 
licensed for the therapy of specific B cell 
lymphomas.10 11 While in the case of these 
hematological cancers the PI3Kδ inhibitors 
are thought to target the cancer cells directly, 
recent studies have demonstrated that inhib-
iting PI3Kδ additionally promotes antitumor 
immunity in both hematological and solid 
cancers, through its preferential dampening 
of Treg.6 12–15 Previous studies have demon-
strated that germline genetic inactivation 
of PI3Kδ in mice results in T cell- mediated 
control of tumor growth.6 Similarly, treating 
mice with a pharmacological inhibitor of 
PI3Kδ is associated with improved control of 
tumor growth.6
PI3K blockade has recently been shown to 
affect the discordant transmission of PI3K in 
dividing T cells.16 17 This asymmetrical local-
ization of PI3K enables activated T cells to give 
rise to daughter cells with either an effector 
or self- renewing phenotype.17 Interestingly, 
the latter T cell type has been shown in many 
studies to exhibit the greatest antitumor 
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capacity both in mouse models and in patients with 
cancer.18–20 It is reasonable therefore to hypothesize that, 
through interfering with this process, PI3Kδ blockade 
biases cell fate in a manner that is favorable to the devel-
opment of robust tumor- specific T cell responses.
Using a mouse model of triple negative breast cancer 
(4T1 cell line) which exhibits the hallmarks of aggressive 
human disease,21 Ali and colleagues previously showed 
that Treg activity is preferentially dampened over other 
T cell subsets on systemic PI3Kδ blockade,6 resulting in 
tumor immunity. We initially repeated these experiments 
with PI3Kδ-blockade and demonstrated that mice can be 
divided into non- regressors (where tumor growth rate 
is reduced but tumors continue to grow) and regres-
sors (where tumors shrink). We used these two groups 
(regressors and non- regressors) to examine the nature 
of Tregs and tumor- specific effector T cells within the 
tumors. This not only allowed us to identify correlates of 
successful tumor immunity, but conversely the key bottle-
neck preventing an effective immune response, and 
in particular, the crucial role of the inhibitory receptor 
LAG3 in controlling this balance.
MATERIALS AND METHODS
Mice and cell lines
Female BALB/c and C57BL/6 mice were purchased from 
Charles River and housed in filter- top cages in specific 
pathogen- free conditions, with standard chow and water 
provided ad libitum. Experiments were conducted in 
accordance with Home Office UK guidelines. The tumor 
cell lines 4T1 (obtained from ATCC (CRL-2539), CT26 
(obtained from ATCC (CRL-2638)) and MC-38 (gift 
from Prof David Withers, University of Birmingham, 
UK) were maintained in culture medium (RPMI 1640, 
10% FCS, 2 mM L- glutamine, 1 mM sodium pyruvate 
and 50 mg/mL penicillin- streptomycin). 1×105 4T1 cells 
were injected subcutaneous into the mammary fat pad, 
5×105 CT26 or MC-38 cells were injected subcutaneously 
into the flank. Tumors were measured from day 7 up to 
three times per week until the mouse was sacrificed and 
tumor measured using digital calipers. The following 
calculation was used to determine tumor volume: 
(length×width×short)×(3.14/6) (where short equals the 
lower of the length and width measurements and provides 
an estimate of height). Tumor weight was measured at 
endpoint following excision of the tumor from the host.
In vivo drug treatment
PI-3065 was provided by Genentech and administered by 
daily oral gavage at 75 mg/kg as described in the original 
paper of Ali and colleagues.6 This dosing of PI-3065 was 
subsequently validated by others to provide selectivity 
for PI3Kδ.22 Vehicle treated mice were given an equiv-
alent volume of carrier solution. Mice were dosed daily 
either from day −1 prior to tumor inoculation or from 
day 7 after tumor inoculation until the termination of the 
experiment. For CD8+ T cell depletion studies, mice were 
administered 400 µg of a CD8- depleting antibody (clone 
YTS169.4) on day 6, 8 and 15 post- tumor inoculation. For 
combination therapy studies, mice were administered 
100 µg of anti- CD69 antibody (clone H1.2F3, Thermo- 
Fisher) or 250 µg of anti- LAG3 antibody (clone C9B7W, 
BioXCell) three times per week from day 10.
Sample dissociation
Tumors were isolated from tumor bearing mice, mechani-
cally disaggregated and then incubated at 37°C for 30 min 
in tumor dissociation mix (HBSS, 10% FCS, 2 mg/mL 
collagenase, 0.03 mg/mL DNAse I). Following incuba-
tion tumor cells were passed through a 40 µm filter and 
washed two times in RPMI supplemented with 10% FCS, 
to yield a single cell suspension.
Flow cytometry
Cells were washed twice with PBS and stained using 
LIVE/DEAD Aqua (Invitrogen) according to the manu-
facturer’s instructions. Cells were washed two times with 
FACS buffer and Fc receptors blocked with anti- CD16/32 
(clone 93; Biolegend). Cells were surface stained with 
the following antibodies: CD3 (Biolegend, 17A2, BV785 
or PECy7), CD4 (Biolegend, GK1.5, BV605, APC, FITC 
or PE), CD8 (Biolegend, 53–6.7, BV421, APC/Fire 750), 
CD45 (Biolegend, 30- F11, PECy7), CD69 (Biolegend, 
H1.2F3, PECy7), PD1 (Biolegend, 29F.1.A12, BV421), 
LAG3 (Biolegend, C9B7W, PE). For intracellular and 
transcription factor staining cells were processed using 
a Foxp3/Transcription factor staining buffer set (eBio-
science) and stained with antibodies, FoxP3 (eBiosci-
ence, FJK- 16s, APC), Ki67 (Biolegend, 11F6, AF488), 
Glut1 (Abcam, EPR3915, AF488), TCF1/7 (Cell Signal-
ling, 6790S, AF647). To enumerate antigen- specific T 
cells the PE- labeled dextramer (H- 2Ld SPSYVYHQ) was 
used according to the manufacturer’s instructions. Mito-
chondrial membrane potential was determined using 
Mitospy- Orange (Biolegend) according to manufactur-
er’s instructions. Cell numbers were compared in tumors 
of individual mice at the same time- points after tumor 
cell inoculation; numbers were therefore normalized per 
gram of tumor tissue.
Dynamic contrast enhanced MRI
Mice were anesthetized and maintained at a body 
temperature of 35°C using an MRI compatible electrical 
heating system23 and a respiration rate of 50–60 breaths 
per min. Dynamic contrast enhanced MRI (DCE- MRI) 
was performed at 7.0 T (VNMRS, Varian) using a 25 mm 
diameter, 35 mm long quadrature birdcage RF coil (Rapid 
Biomedical) operated in transmit/receive mode. Base-
line T1 was measured using a variable flip angle imple-
mentation of a respiratory- gated constant TR 3D gradient 
echo scan (TE=0.64 ms TR=1.60 ms, FA=1–8 deg, isotropic 
resolution of 420 µm), which incorporated dynamic reac-
quisition of data corrupted on entry to each breath.24 B1 
transmission inhomogeneities were corrected using a 
similarly gated Actual Flip Angle Imaging scan. DCE was 
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performed by repeating the three- dimensional gradient 
echo scan 50 times, at FA=5 deg, with Gd contrast agent 
(Omniscan, 30 µL) infused automatically by syringe 
pump (PHD2000, Harvard Apparatus) over 5 s starting at 
the beginning of scan 11/50.
Immunohistochemical staining
Tumors were excised and placed into 10% neutral- 
buffered formalin saline. Fixed tumors were embedded 
into paraffin and 5 µm sections were cut from wild- type 
and mice which carry a point mutation in the ATP- binding 
site of PI3Kδ which renders this kinase inactive (δD910A 
mice25) and from vehicle- treated and PI-3065- treated 
mice. Sections were stained for high endothelial venules 
(HEV) as described previously.26 Briefly, antigen retrieval 
was performed in Tris- EDTA (10 mmol/L; 1 mmol/L, pH 
9.0). Endogenous peroxidase activity was quenched using 
1% H2O2/MeOH and non- specific binding was blocked 
with 2.5% horse serum. Tumor sections were incubated 
overnight at 4°C with rat peripheral node addressin 
(PNAd) (clone MECA79, Biolegend). Sections were 
then washed and incubated in anti- Rat ImmPRESS HRP 
polymer detection reagent (VectorLabs). Slides were incu-
bated briefly in Vector Chromagen DAB HRP substrate 
(Vector Laboratories). Slides were then rinsed with dH2O 
and then counterstained with hematoxylin and mounted 
in DPX. Sections were imaged at 40× magnification using 
a Zeiss Axio Scan.Z1 slide scanner (Plan- Apochromat 
40×/0.95 Korr M27). The total HEV area within each 
tumor was then calculated using Zen software.2 27
In vitro T cell activation assays
CD8+ T cells were purified from splenocytes derived 
from naïve BALB/c mice using negative magnetic bead 
selection kits (Biolegend). CD8+ T cells were labeled with 
Tag- It- Violet (Biolegend) prior to stimulation with 1 µg/
mL CD3/CD28 activator beads (Dynabeads) and 30 IU/
mL IL-2. Cells were left untreated, or treated with vehicle 
(Dimethyl sulfoxide) or 10 µM PI-3065 for 5 days prior to 
flow cytometric analysis.
Statistics
Statistical analysis was performed using Graphpad Prism 
V.8. Unless stated otherwise in the figure legends, data 
are displayed as the mean±SEM. Statistical significance is 
denoted as follows: *p<0.05; **p<0.01; ***p<0.001.
RESULTS
Regressor and non-regressor tumors in mice treated with a 
PI3Kδ inhibitor
It has been previously demonstrated that inactivation of 
PI3Kδ in mice can significantly reduce the growth rate of 
inoculated solid tumors.6 We examined the tumor growth 
rates of mice treated daily with either PI-3065 (PI3Kδ 
inhibitor) or vehicle (dosing control) in the 4T1 breast 
tumor model (figure 1). Confirming previous studies, 
we observed that treatment with PI-3065 resulted in a 
significant reduction in tumor growth rate in the 4T1 
model, (figure 1B). We observed that treatment with 
PI-3065 led to CD8+ T cell- dependent control of primary 
tumor growth (figure 1C) and reduced metastatic burden 
(figure 1D). Overall, these data demonstrate a direct or 
indirect effect of PI-3065 on the ability of CD8+ T cells to 
mount an effective antitumor response.
While tumors from most treated mice exhibited 
reduced growth rates, we found that mice could be 
divided into non- regressors (where tumor growth rate 
was reduced but tumors continued to grow) and regres-
sors (where tumors shrank, approximately 12.5% of the 
mice) (figure 1E,F). When we examined the expansion of 
tumor- specific CD8+ T cells using a tetramer specific for 
the AH1 epitope of the immunodominant 4T1 antigen 
gp70 in tumors that could be definitively designated 
‘regressor’ or ‘non- regressor’ (day 28), we found that a 
significant expansion of gp70- reactive CD8+ T cells was 
only observed in regressing tumors (figure 1G,H).
PI3Kδ inhibition results in accumulation of tumor-infiltrating 
lymphocytes with superior self-renewal capacity
To examine the mechanism underpinning enhanced 
antitumor immunity in PI-3065- treated mice, we first 
addressed whether this inhibitor directly affected CD8+ 
T cells in vitro. It has been previously shown that after 
3–4 rounds of cell division, discordant silencing of TCF1 
becomes apparent in sibling cells as a result of unequal 
transmission of PI3K protein levels between daughter 
cells.16 17 To address whether blockade of PI3Kδ with 
PI-3065 affected asymmetrical expression of TCF1 in 
activated T cells, splenic CD8+ T cells were labeled with 
Tag- it- violet and stimulated for 5 days with anti- CD3 and 
anti- CD28- coupled to beads in the presence or absence of 
PI-3065. While after 3–4 divisions, TCF1 was, as expected, 
reduced in a proportion of the control cells, those treated 
with PI-3065 maintained expression of TCF1 for longer 
(figure 2A,C), implying that PI3Kδ blockade promotes 
their self- renewal capacity, possibly also in vivo, thereby 
promoting tumor immunity.
Since similar tracking of T cell division was not possible in 
the mouse tumors, we surmised that a bias towards TCF1+ 
cells in PI-3065- treated mice would manifest itself as an accu-
mulation of these cells in treated compared with control 
tumors. We therefore assessed frequencies of TCF1+ cells per 
gram of tumor tissue in PI-3065- treated versus control mice, 
including regressor and non- regressor tumors in the anal-
ysis (day 28). An increase in TCF1+ CD4+ and CD8+ tumor- 
infiltrating lymphocyte (TIL) was indeed observed, but only 
in regressor tumors and significantly so in the case of the 
CD4+ T cell population (figure 2D,E). While it is clear that 
regressor tumors are smaller than non- regressor tumors at 
this time- point, it is important to note that a comparison of 
tumors of equivalent size is not possible due to the general 
paucity of infiltrating lymphocytes in small tumors at earlier 
time- points and our inability at these early time- point to distin-
guish between non- regressor and regressor tumors. Overall, 
the data described herein, indicate that successful anticancer 
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Figure 1 Inhibition of PI3Kδ controls 4T1 tumor growth and is dependent on CD8 T cells. (A) Schematic diagram shows the 
experimental protocol: BALB/c mice were treated daily for the duration of the study with either 75 mg/kg of PI-3065 or vehicle 
by oral gavage. One day later mice were inoculated with tumor cells. Tumors were harvested at the time points indicated. (B) 
Tumor growth curves from mice inoculated with 4T1 cells (8–64 mice/group/time- point). (C) Tumor growth curves of mice treated 
with PI-3065 (daily) and anti- CD8 depleting antibody at day 6, 8 and 15 post- tumor inoculation (8 mice/group/time point). (D) 
Number of metastatic colonies in the lungs of tumor bearing mice at day 28 post- tumor inoculation (33–38 mice/group). (E) 
Tumor growth curves and (F) tumor burden from mice treated with PI-3065 who regress their tumor (PI-3065 regressor) or 
mice treated with PI-3065 who slow their tumor growth rate (PI-3065 non- regressor) (11–15 mice/group). (G) Number of gp70 
dextramer+ CD8+ T cells per gram of tumor tissue in vehicle- treated mice, PI-3065 non- regressors and PI-3065 regressors. (H) 
Representative histograms of gp70+ dextramer staining. All data are displayed as the mean±SEM statistical significance was 
determined by multiple unpaired t- test (B, C, E), Mann- Whitney test (D), one- way Analysis of Variance (ANOVA) (F) or Kruskal- 
Wallis test (G). (*p≤0.05, **p≤0.01, ***p≤0.001).
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Figure 2 PI3Kδ activity maintains T cell factor (TCF) expression in the 4T1 model. (A) Representative flow cytometry plots 
showing cell division and TCF1 expression at day 5 in presence of either vehicle or PI-3065. (B) Mean Fluorescence Intensity 
(MFI) of TCF1 expression on CD8+ T cells at division 3, 4 and 5. (C) Percentage of TCFhi CD8+ T cells at divisions 3, 4 and 5. (D) 
Number of tumor infiltrating CD4+ T cells and (E) CD8+ T cells expressing TCF1 at day 28 post- tumor inoculation normalized to 
tumor weight. All data are displayed as the mean±SEM, n=5–21 mice/group. Statistical significance was determined by one- 
way Analysis of Variance (ANOVA) (B, C, D) or Kruskal- Wallis test (E).
copyright.
 o
n
 O
ctober 29, 2020 at Cardiff University. Protected by
http://jitc.bmj.com/
J Im
m
unother Cancer: first published as 10.1136/jitc-2020-000693 on 22 October 2020. Downloaded from 
6 Lauder SN, et al. J Immunother Cancer 2020;8:e000693. doi:10.1136/jitc-2020-000693
Open access 
treatment with a PI3Kδ inhibitor is accompanied by an accu-
mulation of T cells with superior self- renewal capacity.
PI3Kδ inhibition increases T cell fitness and cell surface 
expression of Glut1
During activation and proliferation, T cells use glycolysis to 
meet their metabolic demands, with the inducible glucose 
transporter, Glut1, enabling the necessary glucose uptake 
by T cells. Since TCF1 has been linked to low expression 
of Glut1,17 we wished to examine whether there were 
differences in the metabolic fitness of TIL recovered from 
untreated compared with PI-3065- treated mice. We were 
unable to recover sufficient numbers of CD8+ T cells for 
functional metabolic studies such as oxygen consumption 
rate, even when pooling cells for groups of tumors. We 
therefore used flow cytometry to examine whether mainte-
nance of TCF1 after PI3Kδ-blockade impacted Glut1 expres-
sion on TILs of PI-3065- treated mice. While no differences 
were observed between CD4+ T cell populations recovered 
from the different tumor types, Glut1 was clearly higher on 
CD8+ T cells from PI-3065- treated mice, and significantly 
so on those isolated from regressor tumors (figure 3A,B), 
implying that the cells may undergo glycolytic metabolism. 
Similar findings were observed in vitro where cells stimu-
lated for 5 days with bead- bound anti- CD3- and anti- CD28 
in the presence of PI-3065 retained TCF1 expression, with 
increased expression of cell surface Glut1 (figure 3C,D,E). 
While expression of Glut1 does not necessarily indicate 
that T cells efficiently take up glucose to support glycolytic 
metabolism, it is clear, as shown in figure 3A, that high Glut1 
on CD8+ T cells was significantly associated with regressor 
tumors. Effector T cells require high rates of glucose 
metabolism and it is known that improving the metabolic 
fitness of TIL promotes antitumor responses and successful 
control of tumor burden (reviewed in O'Sullivan et al28).
Figure 3 Inhibition of PI3Kδ increases CD8+ T cell Glut1 expression in the 4T1 model. Mean Fluorescence Intensity (MFI) of 
Glut1 expression on (A) CD4+ and CD8+ tumor infiltrating T cells at day 28 post- tumor inoculation, in vehicle- treated mice and 
PI-3065 treated non- regressor (NR) or tumor regressors (R). (B) Representative histograms of Glut1 staining of CD4 (left panel) 
and CD8 (right panel), open black histogram: vehicle- treated, thick gray line: PI-3065 non- regressor, dashed line: PI-3065 
regressors. (C) MFI of Glut1 on TCFhi CD8+ T cells at divisions 3, 4 and 5. (D) Representative flow cytometry plots showing cell 
division and Glut1 at day 5 in the presence of vehicle or 10 µM PI-3065. (E) Representative flow cytometry plots showing TCF1 
and Glut1 expression in CD8+ T cells that have divided five times in the presence of either vehicle or 10 µM PI-3065 (4–7 mice/
group). Statistical significance was determined by one- way Analysis of Variance (ANOVA) (A, B, C) (*p≤0.05, **p≤0.01).
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As well as glycolytic insufficiency, defective mitochon-
drial function has also been linked to impaired anti-
tumor immune responses.29 We therefore assessed the 
mitochondrial membrane potential in TILs as a proxy 
measure of their energy capacity in treated and control 
tumors. Staining with Mitospy Orange clearly indicated a 
significantly increased mitochondrial membrane poten-
tial in tumor- infiltrating CD4+ and CD8+ T cells from 
treated compared with control mice; this was observed 
in non- regressor as well as regressor mice (figure 4A,B). 
Taken together these data demonstrate that inhibiting 
PI3Kδ confers an enhanced metabolic activity in tumor- 
infiltrating CD8 T cells that positively correlates with 
effective control of tumor growth in these mice.
Since it has previously been shown that Glut1 expres-
sion increases when T cells are activated under hypoxic 
conditions,30 we measured whether at days 10 and 14, 
which just precedes deviation into non- regressor and 
regressor tumors (figure 1), the degree of hypoxia within 
and/or between groups varied. For this purpose, DCE- 
MRI was used as a non- invasive, surrogate measure of 
hypoxia in individual tumors. A reduction in tumor 
perfusion as measured by the area under the curve (iAUC 
at 90 s post Gadolinium injection) was observed by day 
10 in mice given PI-3065, and both vehicle control and 
inhibitor- treated mice by day 14 (figure 4D). Enhance-
ment of the fraction of voxels assessed by DCE- MRI was 
also comparable between the two treatment groups 
(figure 4E,F). Overall, these data indicate that there 
was no relationship between the degree of hypoxia and 
response to treatment.
Phenotypically distinct effector CD8+ T cells are associated 
with successful PI3Kδ-targeted immunotherapy
Sustained signaling is linked to exhaustion of CD8+ T 
cells, characterized by upregulation of inhibitory recep-
tors such as PD1 and LAG3. T cells expressing either or 
both of these receptors are often highly enriched within 
the TILs of many different cancer types (reviewed in 
Nguyen and Ohashi31 32), and we have also observed this 
in human colon cancer.33 We hypothesized that inter-
fering with PI3K signaling by in vivo blockade of PI3Kδ, 
would prevent or slow down exhaustion of TILs. To test 
this, CD8+ TILs in control, non- regressor and regressor 
tumors were compared for expression of PD1 and LAG3 
(figure 5A). While the proportion of LAG3+CD8+ T cells 
was low in all tumor types, no significant differences 
were observed after treatment in both non- regressor 
and regressor tumors. The patterns of PD1 expres-
sion, however, were altered, with a lower proportion of 
CD8+ T cells expressing PD1 in treated compared with 
control mice; a difference which reached significance in 
regressor tumors (figure 5A). This finding implies that 
through attenuating TCR signaling and/or promoting 
Figure 4 Inhibition of PI3Kδ improves intratumoral T cell fitness in the 4T1 model. MFI of Mitospy expression on tumor 
infiltrating (A) CD4+ T cells and (B) CD8+ tumor infiltrating T cells at the indicated day post- tumor inoculation. (C) Representative 
histograms of Mitospy staining of CD4 (left panel) and CD8 (right panel), open histogram: vehicle treated, shaded histogram: 
PI-3065 treated. (D) Initial area under the curve determined by dynamic contrast enhanced (DCE)- MRI. (E) The fraction of 
enhanced voxels during the scan as determined by DCE- MRI. (F) Representative image of a DCE- MRI scan performed at day 
14 post- tumor inoculation. The image displays the contrast enhancement after gadolinium infusion (5–8 mice/group). Statistical 
significance was determined by one- way ANOVA (A) and Kruskal- Wallis test (B) (*p≤0.05, **p≤0.01, ***p≤0.001).
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Figure 5 Successful PI3Kδ inhibition in the 4T1 model results in phenotypically distinct CD8+ tumoral T cells and Tregs. (A) 
Percentage expression of T cell phenotypic markers on CD8+ tumor infiltrating T cells at day 28 post- tumor inoculation. (B) 
Total number and (C) percentage of FoxP3+ CD4+ T cells and present in tumors at day 28 post- tumor inoculation in the three 
treatment groups. Percentage of FoxP3+ CD4+ T cells expressing Ki67 (D), CD69 (E), LAG3 (F) and PD1 (G) at day 28 post- 
tumor inoculation in the three treatment groups. (H and I) Representative high endothelial venules (HEV) staining in 4T1 tumors. 
(J) Percentage HEV area in tumors from wild- type and PI3Kδ kinase dead mice (δD910A) at day 21 post- tumor inoculation. 
(K) Percentage HEV area in tumors from mice in the three treatment groups, squares: vehicle treated, shaded circles: PI-3065 
treated, open circles: PI-3065 treated regressor. All data are displayed as the mean±SEM, N=5–12 mice/group (NR: non- 
regressor, R; regressor). Statistical significance was determined by one- way ANOVA (A, C, E, G), Kruskal- Wallis test (B, D) or 
unpaired T test (J and K). (*p≤0.05, **p≤0.01, ***p≤0.001).
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the accumulation of self- renewing T cells, CD8 T cell 
exhaustion is restrained on PI3Kδ blockade.
Since it has been reported that tumors grow more 
slowly in mice lacking the early activation marker CD69 
(a transmembrane C- Type lectin) or in mice treated with 
CD69- specific antibodies,34 35 we next compared expres-
sion of CD69 on TILs in control and treated tumors. A 
highly significant reduction in the proportion of CD69+ 
CD8+ T cells in regressor compared with both control and 
non- regressor tumors was observed (figure 5A). Overall, 
from this phenotypic analysis, lack of CD69 expression 
emerged as the major feature distinguishing CD8+ TILs 
in regressor tumors, implying that it serves as a key check-
point for successful PI3Kδ-targeted immunotherapy.
Phenotypically distinct Treg are associated with successful 
PI3Kδ-targeted immunotherapy
The previous study by Ali and colleagues showed that 
mice with genetically inactivated PI3Kδ or treated with 
PI-3065, exhibited Treg reduced in number and func-
tional capacity.6 Moreover, the study clearly showed that 
Treg- dysfunction was linked to enhanced antitumor 
immunity.6 We sought to address the impact of PI-3065 
on Treg in regressor versus non- regressor tumors. PI-3065 
treatment significantly reduced both the total number 
of Treg and the proportion of FoxP3+ T cells in TILs 
(figure 5B,C) but neither the number nor proportion of 
Treg distinguished regressor from non- regressor tumors.
Using a different mouse tumor model whereby trans-
genic Treg were depleted with diphtheria toxin, we previ-
ously showed that a successful antitumor T cell response 
was associated with the neogenesis of intratumoral 
HEV.2 27 These studies also showed that T cells, activated 
as a result of Treg- depletion, drove neogenesis of intra-
tumoral HEV.2 We sought to determine whether inacti-
vation of Treg through inhibiting PI3Kδ would have a 
similar effect. We first tested whether this might be the 
case using tumors generated in wild- type (WT) mice and 
PI3Kδ-inactive (PI3KδD910A) mice described previously.13 
The HEV phenotype is characterized by expression of 
PNAd with coexpression of the pan- endothelial cell 
marker, CD31 and a plump and cuboidal morphology 
(figure 5H,I).26 Vessels displaying this phenotype, thus 
confirming the presence of HEV, were detected in 18% 
and 89% of 4T1 tumors in WT and PI3KδD910A mice, 
respectively. The average area of HEVs was calculated 
(µm2) per tumor in these (figure 5J) and in PI-3065- 
treated mice (figure 5K). In the case of the latter, tumor 
tissue collected at days 14 (before regressor and non- 
regressors can be distinguished) and at day 21 (allowing 
regressors and non- regressors to be distinguished) was 
stained for HEV markers. HEV area was measured and 
found to be higher in PI-3065- treated compared with 
control tumors, particularly in regressor tumors. This 
result extends our previous findings in Foxp3- DTR trans-
genic mice to show that neogenesis of intratumoral HEV 
is observed following administration of a therapeutically 
relevant inhibitor of Tregs.2 27
As an additional measure of Treg function, we compared 
Treg in control, non- regressor and regressor tumors for 
expression of PD1 and LAG3 (figure 5F,G).36 The pattern 
of expression within and between tumor types was note-
worthy in so much that a high proportion of PD1+ cells 
corresponded with a low proportion of LAG3+ cells and 
vice versa, implying a degree of compensatory expression 
by the two receptors. The proportion of Treg expressing 
PD1 was significantly reduced in treated tumors, compat-
ible with a reduced function of Treg in these tumors. 
This does not account for tumor regression versus non- 
regression however, as the proportion of PD1+ Treg was 
in fact, higher in regressor tumors. On the other hand, 
the proportion of Treg expressing LAG3 was significantly 
higher in non- regressors compared with both control 
and regressor tumors, implying that LAG3 plays a role in 
maintaining the suppressive function of the remaining 
Treg in non- regressor tumors.36
Finally, since we have previously shown that expression 
of the early activation marker CD69 denotes intratumoral 
Treg with superior suppressive capacity,37 we compared 
CD69 expression in control, non- regressor and regressor 
tumors. We found that Treg remaining in regressor 
tumors were significantly less likely to express CD69 than 
those in control and non- regressor tumors (figure 5E). 
Similarly, proliferation, as measured by Ki67 staining, was 
also reduced among Treg in regressor tumors (figure 5D). 
These data point to the presence of poorly proliferating, 
dysfunctional Treg in regressor tumors whereas the 
remaining Treg in non- regressor tumors may still exert 
suppressive effects.
Combined PI3Kδ and LAG3-blockade elicits superior tumor 
control
As described earlier, a significantly higher proportion 
of Tregs expressing CD69 and particularly LAG3, distin-
guishes tumors that do not regress compared with those 
which do after treatment with PI-3065. Given that there 
was no significant difference in the number of Tregs in 
non- regressor versus regressor tumors, we considered it 
possible that the increase in expression of CD69 and/or 
LAG3, as shown in figure 5, was responsible for failure 
to control tumors by empowering the cells with greater 
suppressor capacity. To address this, we treated mice 
with both PI-3065 and either anti- CD69 or anti- LAG3 
blocking antibodies. Previous studies have demonstrated 
that CD69- deficient mice or those treated with anti- CD69 
antibody therapy have reduced tumor growth rate and 
metastatic burden,35 however, our study clearly demon-
strates that anti- CD69 treatment alone or in combi-
nation with PI-3065 did not result in tumor control 
(online supplemental figure 1A and B). However, when 
anti- LAG3 blocking antibody was used in combination 
with PI-3065 this resulted in a significantly greater tumor 
control than either PI-3065 or anti- LAG3 treatment alone 
(figure 6B–E). Indeed, tumors regressed in 50% of the 
mice treated with the combination compared with mice 
treated with either PI-3065 alone (12%) or LAG3- blockade 
copyright.
 o
n
 O
ctober 29, 2020 at Cardiff University. Protected by
http://jitc.bmj.com/
J Im
m
unother Cancer: first published as 10.1136/jitc-2020-000693 on 22 October 2020. Downloaded from 
10 Lauder SN, et al. J Immunother Cancer 2020;8:e000693. doi:10.1136/jitc-2020-000693
Open access 
alone (0%) (figure 6C,D). Moreover, this was accompa-
nied by a significant increase in the number of tumor- 
infiltrating AH1- specific CD8+ T cells (figure 6F).
We next sought to determine whether treatment with 
PI-3065 alone or in combination with LAG3- blockade, 
would enable control of other tumors, namely the colon 
carcinoma cell- lines, CT26 and MC38. We first found that 
while CT26 is responsive to PI-3065 treatment (figure 7A,B), 
the effect of PI-3065 treatment on the growth of MC-38 
tumors was negligible (online supplemental figure 2 B 
& C). A comparison of TILs in each tumor type revealed 
that while the ratio of CD8+ T cells to Treg was markedly 
increased after treatment of 4T1 and CT26 tumors, this 
was not the case for MC38 tumors (8.51 and 4.84, respec-
tively compared with 1.30; online supplemental figure 
3), indicating that immunosuppression in MC38 tumors 
cannot be overcome by targeting PI3Kδ. As described 
earlier for 4T1 tumors, administration of anti- LAG3 anti-
bodies had no effect on growth of either CT26 or MC-38 
tumors when used alone. However, similar to the response 
in 4T1 tumors, combination therapy elicited superior 
tumor control of CT26 tumors while no effect was seen in 
the case of MC38 tumors (figure 7B, online supplemental 
figure 2 D & E). These data indicate that a robust response 
to the PI3Kδ-inhibitor, as observed for 4T1 and CT26 but 
not MC38 tumors, is an essential prerequisite to a thera-
peutic effect of anti- LAG3 antibodies.
LAG-3 blockade in combination with vehicle had no 
visible effect on the health of the mice. However, in the 
case of mice bearing 4T1 tumors, LAG3 blockade in 
combination with PI-3065 resulted in the development 
of varying degrees of autoimmunity with all animals 
developing a starry coat and inflammation of the skin a 
week after commencing dual treatment. Furthermore, 
in animals with slower growing but not regressing 4T1 
tumors (50%), splenomegaly and lymphadenopathy was 
evident. Mice treated with PI-3065 only exhibited mild 
starring coat in the final week of treatment. No animal, 
in any of the treatment groups, displayed weight loss or 
signs of colitis.
Figure 6 Anti- LAG3 and PI3Kδ combination therapy significantly reduces tumor burden in 4 T1 cells. (A) Schematic diagram 
showing the experimental protocol: BALB/c mice were treated daily for the duration of the study with either 75 mg/kg of PI-3065 
or vehicle by oral gavage and were administered anti- LAG3 (250 µg) at the days indicated (6–8 mice/group). (B) Tumor growth 
curves from mice treated with (B) vehicle (C) PI-3065 (D) vehicle +anti- LAG3 or (E) PI-3065 +anti- LAG3 vehicle. (F) number of 
gp70 dextramer+ CD8+ T cells per gram of tumor tissue (NR: non- regressor, R; regressor). (G) Schematic diagram illustrating the 
experimental therapeutic strategy employed: BALB/c mice were inoculated with tumors and daily treatment with either 75 mg/
kg of PI-3065 or vehicle by oral gavage commenced once tumors became palpable. Anti- LAG3 (250 µg) was administered at 
the days indicated (6–8 mice/group). Tumor growth curves from therapeutic strategy mice treated with (H) vehicle (I) PI-3065 
(J) vehicle+anti- LAG3 or (K) PI-3065+anti- LAG3. All data are displayed as the mean±SEM statistical significance was Kruskal- 
Wallis test (**p≤0.01, ***p≤0.001).
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Finally, to address the potential utility of PI3Kδ inhibition 
in therapeutic setting, we commenced PI-3065 treatment 
once tumors became palpable (day 7 post- tumor inocu-
lation) either alone or in combination with anti- LAG3. 
While PI-3065 treatment alone significantly slowed tumor 
growth compared with vehicle (figure 6H,I), a delay in 
starting treatment did not result in any mice capable 
of regressing their tumors. However, when combina-
tion treatment with PI-3065 and anti- LAG3, as observed 
earlier, enhanced control of tumor growth, with clear-
ance of tumors in some animals (figure 6J,K).
DISCUSSION
In 2014, Ali and colleagues used mice with genetically 
inactive PI3Kδ to demonstrate the requirement of this 
signaling protein for optimal Treg function. Mice bearing 
inactive PI3Kδ demonstrated enhanced tumor immu-
nity; a finding which was recapitulated using the PI-3065 
small molecule inhibitor of PI3Kδ.6 In an extension of 
this work, we have examined the impact of PI-3065 on 
Treg and intratumoral effector T cells identifying within 
the latter population, increased proliferation of antigen- 
specific T cells, enhanced self- renewal capacity, metabolic 
fitness and resistance to exhaustion as key consequences 
of successful PI3Kδ-targeted immunotherapy. Treatment 
with PI-3065 resulted in neogenesis of intratumoral 
HEV. Presence of HEV in tumors has been associated 
with a superior antitumor effector T cell response as a 
result of their ability to support migration of naïve and 
central memory T cells into the tumor. Thus, in the 
case of PI3Kδ-targeted immunotherapy, HEV may serve 
an important role in shaping the type and number of 
effector T cells entering the tumor mass.
Mice inoculated with 4T1 tumor cells and treated with 
PI-3065 could be divided into two groups, namely regres-
sors and non- regressors. An interrogation of effector 
T cells revealed that a greater expansion of CD8+ T 
cells specific for the immunodominant 4T1 antigen, 
AH1,38 was observed in regressor compared with non- 
regressors and control tumors. Significant differences 
were also observed in the Treg populations. Treatment 
reduced Treg numbers in both tumor types, although 
Figure 7 Anti- LAG3 and PI3Kδ combination therapy significantly reduces tumor burden in the CT26 model of colon 
adenocarcinoma. (A) Schematic diagram showing the experimental protocol: BALB/c mice were treated daily for the duration 
of the study with either 75 mg/kg of PI-3065 or vehicle by oral gavage and were administered anti- LAG3 (250 µg) at the days 
indicated (12–14 mice/group). (B) Tumor growth curves of mice inoculated with CT26 cells and treated with either vehicle, 
vehicle+anti- LAG3, PI-3065, or PI-3065+anti- LAG3. (C) Percentage of LAG3+ FoxP3+ Tregs in the tumors at day 24 post- tumor 
inoculation in the two treatment groups. All data are displayed as the mean±SEM. Statistical significance was determined by 
multiple unpaired t- test (*p≤0.05, ***p≤0.001).
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the number of proliferating Treg was significantly lower 
in regressor tumors. Other key markers of Treg activity, 
namely CD69 and LAG3, also distinguished regressors 
and non- regressors. We have previously reported that 
highly proliferative, CD69+ Treg demonstrate superior 
suppressive capacity37; a finding which is in line with 
studies demonstrating that the enhanced suppressive 
function of CD69+ Treg significantly increases their ability 
to control autoimmune disease.39 However, while the 
proportion of Treg expressing CD69 is significantly lower 
in regressor compared with non- regressor 4T1 tumors, 
and despite previous reports,35 administration of CD69- 
specific antibodies in vivo did not improve tumor control 
in the 4T1 model. As mentioned earlier, the propor-
tion of Treg expressing LAG3 was increased on treat-
ment with PI-3065, particularly in non- regressor tumors. 
This may be explained by pre- existing LAG3+ Treg cells 
which, while avoiding the Treg- inhibitory effects of 
PI3Kδ-blockade, expand in response to the inflammation 
caused by PI-3065 administration. To target these cells, 
as well as LAG3+ CD8+ T cells, we determined whether 
LAG3- blocking antibodies would improve control of 
tumor growth. The results were striking showing in both 
4T1 and CT26 tumor models, that the combination of 
PI3Kδ-blockade and anti- LAG3 antibodies significantly 
improved control of tumor growth. It is possible that 
PI3Kδ-blockade and anti- LAG3 antibodies both improve 
antitumor immunity indirectly through targeting Tregs 
and directly, through targeting effector T cells. It is clear 
however that not all tumors behave similarly. When 
we used the colon- derived cancer cell line MC-38, we 
observed a poor response to PI3Kδ-blockade, which 
could not be improved by the addition of LAG3- specific 
antibodies, suggesting other immunosuppressive mecha-
nisms dominate in these tumors. Indeed, previous studies 
have demonstrated that MC38 tumors are far less suscep-
tible to Treg inhibition than other tumor models, indi-
cating that resistance to immunotherapy is provided by 
alternative cellular mechanisms.40 41 Furthermore, a study 
by Gyori and colleagues demonstrated that MC38 tumors 
were non- responsive to the PI3Kδ inhibitor, Idelal-
isib, and could only be controlled when therapies that 
targeted both Tregs and tumor- associated macrophages 
were employed together.42 It appears that an alteration in 
the CD8:Treg ratio is a requisite of successful PI3Kδ inhi-
bition. In tumors, such as MC38, that fail to increase the 
CD8:Treg ratio following PI3Kδ inhibition, then second 
immunotherapies that target either Tregs or effector T 
cells are likely to prove ineffective. Our data point to the 
importance of assessing T cell subsets and phenotype 
where possible in order to identify tumor- specific bottle-
necks, including those that arise in response to treatment. 
Accumulating this information will provide a framework 
to aid translational studies and guide selection of combi-
nation therapies. This will likely also be of key importance 
for the PI3Kδ inhibitors progressing in clinical trials in 
solid tumors, which include parsaclisib in combina-
tion with anti- PD1 in a range of advanced solid tumor 
indications (NCT02646748/NCT03589651), AMG-319 as 
monotherapy in a window- trial in Head and Neck cancer 
(Cancer Research UK and Amgen; NCT02540928) and 
IOA-244 (iOnctura) as monotherapy and in combination 
with pemetrexed/cisplatin in a range of advanced solid 
tumor indications (NCT04328844).
We further sought to improve the therapeutic rele-
vance of our model by extending experiments to the 
treatment of mice with established 4T1 tumors. While 
PI3Kδ-blockade had some effect on control of established 
tumors, regression was observed on sequential adminis-
tration of LAG3- specific antibodies, demonstrating the 
potential clinical utility of our findings.
Interestingly, the superior tumor immunity provided 
by PI-3065 and anti- LAG3 combination treatment was 
accompanied by autoimmunity. While this is a wide-
spread finding in patients exhibiting successful tumor 
responses following immunotherapy with CTLA4- specific 
with or without PD1- specific antibodies, adverse inflam-
matory effects are not commonly found in mice treated 
in a similar way. The mouse model presented herein 
may therefore prove useful for probing the mechanisms 
underpinning concurrent autoimmunity and tumor 
immunity and for testing approaches for minimizing the 
former while maximizing the latter.
CONCLUSIONS
This study demonstrates that treating mice with the PI-3065 
small molecule inhibitor of PI3Kδ can promote control of 
tumor growth. A successful response is characterized by an 
increased population of TCF1+ CD69- T cells that can self- 
renew, and continuously maintain a pool of effector cells 
that are able to efficiently use the available glucose and resist 
exhaustion. The study further identifies LAG3 as a critical 
checkpoint which diminishes the impact of PI3Kδ blockade, 
with combination treatment with PI-3065 and anti- LAG3 
providing superior antitumor control over single agent 
therapy. Identification and sequential targeting of immune 
checkpoints provides an exciting route for combination 
therapy with PI3Kδ blockade.
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